TMDX Stock Recent News
TMDX LATEST HEADLINES
In this video, I will talk about TransMedics (TMDX -5.16%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.
BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco announces that it is investigating potential securities law violations by TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX). About the Investigation On January 10, 2025, Bloomberg reported TransMedics shares dropped “as much as 13% after Scorpion Capital said it is short the transplant-therapy company's stock.
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2025 / Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX) stock after the Company's stock price dropped significantly during intraday trading today.
Shares of TransMedics Group (TMDX -12.34%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday.
Shares of TransMedics Group are down following an investigative report by Scorpion Capital. Block & Leviton is investigating TMDX for securities fraud.
At the intersection of healthcare and technology, medtech companies are leveraging innovative solutions to improve patient care and health outcomes. Industry leaders are well-positioned to deliver shareholder value by addressing the growing healthcare demands of an aging global population and the rising prevalence of chronic diseases.
Shares of Transmedics (TMDX 9.47%) fell 28.1% in December, according to data from S&P Global Market Intelligence.
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.
TransMedics is transforming organ transplants with advanced technology and integrated logistics. Strong market demand and expanding adoption support long-term growth potential despite the recent top-line deceleration. Following the recent nosedive, the stock's current valuation offers an attractive entry point for a market leader in a critical industry.